1. A Phase II clinical trial of a mixture of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. (6th June 2013) Authors: Shirahata, A.; Fukutake, K.; Takamatsu, J.; Shima, M.; Hanabusa, H.; Mugishima, H.; Amano, K.; Takedani, H.; Tamashima, S.; Matsushita, T.; Tawa, A.; Tanaka, I.; Higasa, S.; Kosaka, Y.; Fujii, T.; Sakai, M.; Migita, M.; Kawakami, K.; Ohashi, Y.; Saito, H. Journal: Haemophilia Issue: Volume 19:Number 6(2013:Nov.) Page Start: 853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Issue 1 (1st August 2016) Authors: Shinkoda, Y.; Shirahata, A.; Fukutake, K.; Takamatsu, J.; Shima, M.; Hanabusa, H.; Mugishima, H.; Takedani, H.; Kawasugi, K.; Taki, M.; Matsushita, T.; Tawa, A.; Nogami, K.; Higasa, S.; Kosaka, Y.; Fujii, T.; Sakai, M.; Migita, M.; Uchiba, M.; Kawakami, K. Journal: Haemophilia Issue: Volume 23:Issue 1(2017) Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗